Related Experiment Video
Updated: May 15, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration
Huijing Feng1, Yang Xia2, Wenxian Wang3
1Department of Thoracic Oncology, Shanxi Academy of Medical Sciences, Shanxi Bethune Hospital, Taiyuan 030032, China.
Abstract:
Alterations in the mesenchymal-epithelial transition factor (MET) gene are critical drivers of non-small cell lung cancer (NSCLC). In recent years advances in precision therapies targeting MET alterations have significantly expanded treatment options for NSCLC patients. These alterations include MET exon 14 skipping mutations (MET exon 14 skipping), MET gene amplifications, MET point mutations (primarily kinase domain mutations), and MET protein overexpression. Accurate identification of these alterations and appropriate selection of patient populations and targeted therapies are essential for improving clinical outcomes. The East China Lung Cancer Group, Youth Committee (ECLUNG YOUNG, Yangtze River Delta Lung Cancer Cooperation Group) has synthesized insights from China's innovative drug development landscape and clinical practice to formulate an expert consensus on the diagnosis and treatment of NSCLC patients with MET alterations. This consensus addresses key areas, such as optimal testing timing, testing methods, testing strategies, quality control measures, and treatment approaches. By offering standardized recommendations, this guidance aims to streamline diagnostic and therapeutic processes and enhance clinical decision-making for NSCLC with MET alterations.
Insights
This expert consensus provides guidance on diagnosing and treating non-small cell lung cancer (NSCLC) with MET alterations. It aims to standardize testing and treatment, improving outcomes for patients with MET-driven lung cancer.
Area of Science:
- Oncology
- Genetics
- Precision Medicine
Background:
- Alterations in the MET gene are key drivers of non-small cell lung cancer (NSCLC).
- Targeted therapies for MET alterations have improved treatment options for NSCLC patients.
- MET alterations include exon 14 skipping, amplifications, point mutations, and protein overexpression.
Purpose of the Study:
- To formulate an expert consensus on diagnosing and treating NSCLC patients with MET alterations.
- To synthesize insights from China's drug development and clinical practice.
- To provide standardized recommendations for testing and treatment.
Main Methods:
- Expert consensus development by the East China Lung Cancer Group, Youth Committee (ECLUNG YOUNG).
- Synthesis of data from China's innovative drug development landscape and clinical practice.
- Addressing key areas: testing timing, methods, strategies, quality control, and treatment.
Main Results:
- The consensus offers standardized recommendations for NSCLC with MET alterations.
- It aims to streamline diagnostic and therapeutic processes.
- Enhanced clinical decision-making for MET-altered NSCLC is a key outcome.
Conclusions:
- Accurate identification of MET alterations is crucial for effective treatment selection.
- Standardized approaches improve clinical outcomes for NSCLC patients with MET alterations.
- This guidance facilitates better management of MET-driven NSCLC.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016